Zhao Hongda

Zhao Hongda is a scientist at FibroGen since August 2008, focusing on the discovery of small molecule Prolyl-hydroxylase Inhibitors (PHIs) aimed at treating anemia, providing cardioprotection, and developing cancer therapies, along with process development for intermediate-size scale-up to support preclinical development. Prior experience includes a role as a Postdoctoral Research Fellow at the University of Texas Southwestern Medical Center from May 2006 to May 2008, where Zhao synthesized and derivatized cyclic peptides to create a series of structurally diverse compounds and utilized reverse-phase HPLC for product separation. Additionally, Zhao held the position of Group Leader at Chempacific Corp in 2008, supervising and conducting API synthesis under cGMP conditions. Zhao earned a Ph.D. in Synthetic Organic Chemistry from The University of Texas at Austin between 2001 and 2006, following a Master of Science in the same field from Tulane University from 1999 to 2001.